Belite Bio (BLTE) Set to Announce Earnings on Tuesday

Belite Bio (NASDAQ:BLTE - Get Free Report) will be posting its quarterly earnings results after the market closes on Tuesday, November 12th. Analysts expect Belite Bio to post earnings of ($0.30) per share for the quarter. Investors interested in registering for the company's conference call can do so using this link.

Belite Bio (NASDAQ:BLTE - Get Free Report) last issued its quarterly earnings data on Friday, August 9th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.03). On average, analysts expect Belite Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Belite Bio Stock Up 15.7 %

NASDAQ BLTE traded up $10.98 on Wednesday, hitting $81.08. The stock had a trading volume of 197,708 shares, compared to its average volume of 52,863. The company's 50-day moving average is $53.93 and its two-hundred day moving average is $49.25. The stock has a market cap of $2.48 billion, a price-to-earnings ratio of -65.22 and a beta of -1.60. Belite Bio has a one year low of $31.00 and a one year high of $82.25.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Benchmark reissued a "buy" rating and set a $57.00 price target on shares of Belite Bio in a report on Tuesday, August 13th. HC Wainwright reissued a "buy" rating and set a $60.00 target price on shares of Belite Bio in a report on Thursday, September 12th.

Belite Bio Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.